Your browser doesn't support javascript.
loading
Polymorphisms within autophagy-related genes as susceptibility biomarkers for pancreatic cancer: A meta-analysis of three large European cohorts and functional characterization.
Gálvez-Montosa, Fernando; Peduzzi, Giulia; Sanchez-Maldonado, José Manuel; Ter Horst, Rob; Cabrera-Serrano, Antonio J; Gentiluomo, Manuel; Macauda, Angelica; Luque, Natalia; Ünal, Pelin; García-Verdejo, Francisco Javier; Li, Yang; López López, José Antonio; Stein, Angelika; Bueno-de-Mesquita, H Bas; Arcidiacono, Paolo Giorgio; Zanette, Dalila Luciola; Kahlert, Christoph; Perri, Francesco; Soucek, Pavel; Talar-Wojnarowska, Renata; Theodoropoulos, George E; Izbicki, Jakob R; Tamás, Hussein; Van Laarhoven, Hanneke; Nappo, Gennaro; Petrone, Maria Chiara; Lovecek, Martin; Vermeulen, Roel C H; Adamonis, Kestutis; Reyes-Zurita, Fernando Jesus; Holleczek, Bernd; Sumskiene, Jolanta; Mohelníková-Duchonová, Beatrice; Lawlor, Rita T; Pezzilli, Raffaele; Aoki, Mateus Nobrega; Pasquali, Claudio; Petrenkiene, Vitalija; Basso, Daniela; Bunduc, Stefania; Comandatore, Annalisa; Brenner, Hermann; Ermini, Stefano; Vanella, Giuseppe; Goetz, Mara R; Archibugi, Livia; Lucchesi, Maurizio; Uzunoglu, Faik Guntac; Busch, Olivier; Milanetto, Anna Caterina.
Afiliação
  • Gálvez-Montosa F; Department of Medical Oncology, Complejo Hospitalario de Jaén, Jaén, Spain.
  • Peduzzi G; Department of Biology, University of Pisa, Pisa, Italy.
  • Sanchez-Maldonado JM; Department of Biochemistry and Molecular Biology I, University of Granada, Granada, Spain.
  • Ter Horst R; Genomic Oncology Area, GENYO, Centre for Genomics and Oncological Research: Pfizer/University of Granada/Andalusian Regional Government, PTS, Granada, Spain.
  • Cabrera-Serrano AJ; Instituto de Investigación Biosanataria Ibs.Granada, Granada, Spain.
  • Gentiluomo M; Genomic Epidemiology Group, German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Macauda A; Department of Internal Medicine and Radboud Center for Infectious Diseases, Radboud University Medical Center, Nijmegen, The Netherlands.
  • Luque N; CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria.
  • Ünal P; Genomic Oncology Area, GENYO, Centre for Genomics and Oncological Research: Pfizer/University of Granada/Andalusian Regional Government, PTS, Granada, Spain.
  • García-Verdejo FJ; Instituto de Investigación Biosanataria Ibs.Granada, Granada, Spain.
  • Li Y; Department of Biology, University of Pisa, Pisa, Italy.
  • López López JA; Genomic Epidemiology Group, German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Stein A; Department of Medical Oncology, Complejo Hospitalario de Jaén, Jaén, Spain.
  • Bueno-de-Mesquita HB; Genomic Epidemiology Group, German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Arcidiacono PG; Department of Medical Oncology, Complejo Hospitalario de Jaén, Jaén, Spain.
  • Zanette DL; Department of Internal Medicine and Radboud Center for Infectious Diseases, Radboud University Medical Center, Nijmegen, The Netherlands.
  • Kahlert C; CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria.
  • Perri F; Department of Medical Oncology, Complejo Hospitalario de Jaén, Jaén, Spain.
  • Soucek P; Genomic Epidemiology Group, German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Talar-Wojnarowska R; National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands.
  • Theodoropoulos GE; Pancreatico/Biliary Endoscopy & Endosonography Division, Pancreas Translational & Clinical Research Center, San Raffaele Scientific Institute, Milan, Italy.
  • Izbicki JR; Laboratory for Applied Science and Technology in Health, Carlos Chagas Institute, Oswaldo Cruz Foundation (Fiocruz), Curitiba, Brazil.
  • Tamás H; Department of General Surgery, University of Heidelberg, Heidelberg, Baden-Württemberg, Germany.
  • Van Laarhoven H; Division of Gastroenterology and Research Laboratory, Fondazione IRCCS "Casa Sollievo della Sofferenza" Hospital, Foggia, Italy.
  • Nappo G; Biomedical Center, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic.
  • Petrone MC; Department of Digestive Tract Diseases, Medical University of Lodz, Lodz, Poland.
  • Lovecek M; Colorectal Unit, First Department of Propaedeutic Surgery, Medical School of National and Kapodistrian University of Athens, Hippocration General Hospital, Athens, Greece.
  • Vermeulen RCH; Department of General, Visceral and Thoracic Surgery, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
  • Adamonis K; Center for Translational Medicine, Semmelweis University, Budapest, Hungary.
  • Reyes-Zurita FJ; Division of Pancreatic Diseases, Heart and Vascular Center, Semmelweis University, Budapest, Hungary.
  • Holleczek B; Department of Medical Oncology, Amsterdam UMC location University of Amsterdam, Amsterdam, The Netherlands.
  • Sumskiene J; Cancer Center Amsterdam, Imaging and Biomarkers, Amsterdam, The Netherlands.
  • Mohelníková-Duchonová B; Pancreatic Unit, IRCCS Humanitas Research Hospital, Milan, Italy.
  • Lawlor RT; Department of Biomedical Sciences, Humanitas University, Milan, Italy.
  • Pezzilli R; Pancreatico/Biliary Endoscopy & Endosonography Division, Pancreas Translational & Clinical Research Center, San Raffaele Scientific Institute, Milan, Italy.
  • Aoki MN; Department of Surgery I, University Hospital Olomouc, Olomouc, Czech Republic.
  • Pasquali C; University of Utrecht, Utrecht, The Netherlands.
  • Petrenkiene V; Gastroenterology Department and Institute for Digestive Research, Lithuanian University of Health Sciences, Kaunas, Lithuania.
  • Basso D; Department of Biochemistry and Molecular Biology I, University of Granada, Granada, Spain.
  • Bunduc S; Saarland Cancer Registry, Saarbrücken, Germany.
  • Comandatore A; Division of Clinical Epidemiology and Aging Research, German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Brenner H; Gastroenterology Department and Institute for Digestive Research, Lithuanian University of Health Sciences, Kaunas, Lithuania.
  • Ermini S; Toxicogenomics Unit, National Institute of Public Health, Prague, Czech Republic.
  • Vanella G; ARC-Net Centre for Applied Research on Cancer University of Verona, Verona, Italy.
  • Goetz MR; Department of Diagnostics and Public Health, Section of Pathology, University of Verona, Verona, Italy.
  • Archibugi L; Potenza County Medical Association, Potenza, Italy.
  • Lucchesi M; Laboratory for Applied Science and Technology in Health, Carlos Chagas Institute, Oswaldo Cruz Foundation (Fiocruz), Curitiba, Brazil.
  • Uzunoglu FG; Department of DISCOG, University of Padova, Padova, Italy.
  • Busch O; Gastroenterology Department and Institute for Digestive Research, Lithuanian University of Health Sciences, Kaunas, Lithuania.
  • Milanetto AC; Department of DIMED, Laboratory Medicine, University of Padova, Padova, Italy.
Int J Cancer ; 2024 Sep 25.
Article em En | MEDLINE | ID: mdl-39319538
ABSTRACT
Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal cancers with patients having unresectable or metastatic disease at diagnosis, with poor prognosis and very short survival. Given that genetic variation within autophagy-related genes influences autophagic flux and susceptibility to solid cancers, we decided to investigate whether 55,583 single nucleotide polymorphisms (SNPs) within 234 autophagy-related genes could influence the risk of developing PDAC in three large independent cohorts of European ancestry including 12,754 PDAC cases and 324,926 controls. The meta-analysis of these populations identified, for the first time, the association of the BIDrs9604789 variant with an increased risk of developing the disease (ORMeta = 1.31, p = 9.67 × 10-6). We also confirmed the association of TP63rs1515496 and TP63rs35389543 variants with PDAC risk (OR = 0.89, p = 6.27 × 10-8 and OR = 1.16, p = 2.74 × 10-5). Although it is known that BID induces autophagy and TP63 promotes cell growth, cell motility and invasion, we also found that carriers of the TP63rs1515496G allele had increased numbers of FOXP3+ Helios+ T regulatory cells and CD45RA+ T regulatory cells (p = 7.67 × 10-4 and p = 1.56 × 10-3), but also decreased levels of CD4+ T regulatory cells (p = 7.86 × 10-4). These results were in agreement with research suggesting that the TP63rs1515496 variant alters binding sites for FOXA1 and CTCF, which are transcription factors involved in modulating specific subsets of regulatory T cells. In conclusion, this study identifies BID as new susceptibility locus for PDAC and confirms previous studies suggesting that the TP63 gene is involved in the development of PDAC. This study also suggests new pathogenic mechanisms of the TP63 locus in PDAC.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article